---
schema_version: "secwatch.filing_event.v1"
accession: "0000320017-23-000003"
form_type: "8-K"
ticker: "LSTA"
cik: "0000320017"
company_name: "LISATA THERAPEUTICS, INC."
filed_at: "2023-02-06T23:59:59+00:00"
generated_at: "2026-06-20T00:32:15.766962+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Lisata's LSTA201 trial in diabetic kidney disease fails to show consistent kidney function improvement

## Summary
- Preliminary unaudited cash, equivalents and marketable securities of ~$69.2M as of Dec 31, 2022.
- Phase 1b trial of LSTA201 (CD34+ cell therapy) in 6 DKD patients tolerated but no consistent kidney function improvement.
- Company will evaluate data and determine next steps; no further clinical study committed.
- Corporate presentation attached as Exhibit 99.1 for investor conference use.

## SEC filing metadata
- accession: 0000320017-23-000003
- form_type: 8-K
- ticker: LSTA
- cik: 0000320017
- company_name: LISATA THERAPEUTICS, INC.
- filed_at: 2023-02-06T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/320017/000032001723000003/0000320017-23-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/320017/000032001723000003/clbs-20230206.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000320017-23-000003
- JSON: https://secwatch.observer/filing/0000320017-23-000003.json
- Plain text: https://secwatch.observer/filing/0000320017-23-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.